Susan McClory

Assistant Professor

Children's Hospital of Philadelphia

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Susan McClory is an Assistant Professor at the Children's Hospital of Philadelphia, USA. Her research primarily focuses on immunotherapy and hematopoietic stem cell transplantation, particularly in relation to B-cell acute lymphoblastic leukemia and immune dysregulatory disorders. Recent publications include significant findings on CAR T cell therapies and the roles of various regulators in T cell differentiation and memory programming.

Articles (9)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2020

Collaborators (2)

Robert Faryabi

University of Pennsylvania

UNITED STATES

View details

Zhuang Miao

Stanford University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Susan McClory

Research Interests

Explore related searches

Contact this professor

About

Articles (9)

CD22-targeted chimeric antigen receptor-modified T cells for children and adults with relapse of B-cell acute lymphoblastic leukemia after CD19-directed immunotherapy

Correction to: FOXO1 is a master regulator of memory programming in CAR T cells (Nature, (2024), 629, 8010, (211-218), 10.1038/s41586-024-07300-8)

FOXO1 is a master regulator of memory programming in CAR T cells

Transplantation for immune dysregulatory disorders: current themes and future expectations

Single-cell CAR T atlas reveals type 2 function in 8-year leukaemia remission

Hematopoietic stem cell transplantation for primary immunodeficiency

The pseudokinase Trib1 regulates the transition of exhausted T cells to a KLR<sup>+</sup> CD8<sup>+</sup> effector state, and its deletion improves checkpoint blockade.

The Current State of Chimeric Antigen Receptor T Cell Therapy for B Lymphoblastic Leukemia.

Trib1 regulates T cell differentiation during chronic infection by restraining the effector program.

Collaborators (2)

Robert Faryabi

Zhuang Miao

Make your next move.